Skip to main content

Start your patients on the #1 prescribed prostacyclin treatment.1*

Learn more

FOR US HEALTHCARE PROFESSIONALS ONLY

For the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.

FOR US HEALTHCARE PROFESSIONALS ONLY

Request a Rep Referral Form
REFERRAL FORM

MECHANISM OF ACTION

TYVASO (treprostinil) is a direct-to-lung, inhaled prostacyclin mimetic2

Treprostinil is a prostacyclin-class therapy, with a mechanism of action (MOA) that targets 3 of the major pathologic changes that occur in PAH.2,3

Vessel Affected by PAH2,3
TYVASO (inhaled prostacyclin) mechanism of action

  1. Vasoconstriction

    Trepostinil directly dilates pulmonary and systemic arterial vascular beds

  2. Platelet aggregation

    Trepostinil inhibits platelet aggregation

  3. Smooth muscle proliferation

    Trepostinil inhibits smooth muscle cell proliferation

Learn more about the demonstrated safety and benefits of TYVASO.

SEE THE BENEFITS
Patient standing in a park with a yoga mat rolled up and hanging on shoulder

Treat at the site of disease2,4

TYVASO working in the lungs
  • TYVASO is delivered directly to the lungs, which are highly vascularized, providing an enormous surface area for drug absorption and an attractive target for drug delivery2,4,5
  • TYVASO is inhaled directly to distal airspaces that are in close proximity to pulmonary arterioles affected by PAH6

Direct-to-lung delivery results in higher concentrations in the pulmonary arterial vasculature, which may selectively enhance blood flow for better ventilation and perfusion matching with less off-target exposure.4

TYVASO devices

TYVASO is delivered via 2 device options: a Dry Powder Inhaler (DPI) or a nebulizer.

TYVASO DPI inhaler
TYVASO DPI
TYVASO Nebulizer inhaler